Preferred Label : repotrectinib;
MeSH Hyperonym : 1,15-Etheno-1H-pyrazolo(4,3-f)(1,4,8,10)benzoxatriazacyclotridecin-4(5H)-one, 11-fluoro-2,6,7,13-tetrahydro-7,13-dimethyl-,
(14Z)-;
UNII : 08O3FQ4UNP;
Origin ID : C000708510;
UMLS CUI : C4524909;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- (1Z)-6-Fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentaazatetracyclo(13.5.2.04,9.018,22)docosa-1,4,6,8,15,19,21-heptaen-14-one [MeSH concept]
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.ema.europa.eu/en/medicines/human/EPAR/augtyro
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
repotrectinib
repotrectinib
antineoplastic agents
antineoplastic agents
drug approval
europe
repotrectinib
adult
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
ROS1 Fusion Gene Positive
Advanced Lung Non-Small Cell Carcinoma
adolescent
NTRK Fusion Gene Positive
Solid Neoplasm
Solid Neoplasm
administration, oral
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
Anaplastic Lymphoma Kinase
ROS1 protein, human
receptor, trkc
receptor, trkb
receptor, trka
drug evaluation, preclinical
---
